ArticleFrontiers in pharmacology2026
Formulation of hispidulin-loaded sodium carboxymethyl cellulose nanoparticles: characterisation, biological activities and molecular insights.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hispidulin is a bioactive flavonoid with promising antioxidant and anticancer properties; however, its poor aqueous solubility and stability limit its usage in therapeutic application. This study aimed to develop a suitable nanocarrier system to enhance its bioavailability and biological efficacy. Methods: Hispidulin-loaded sodium carboxymethyl cellulose nanoparticles (HIS-CMC NPs) were synthesised via ionic gelation. Physicochemical characterisation was performed using UV-Vis, FTIR, XRD, DLS and TGA, along with microscopic analysis. Encapsulation efficiency and drug loading were determined. Results: The HIS-CMC NPs showed a hydrodynamic size of 243.3 nm and a zeta potential of -39.1 mV, indicating good stability. High encapsulation efficiency (94.84% ± 1.2%) and drug loading (35.13% ± 1.5%) were achieved. Sustained drug release (87.5% ± 1.3%, pH 5.4) followed Korsmeyer-Peppas kinetics. The nanoparticles exhibited enhanced antioxidant, anti-inflammatory and metal chelating activities compared to free hispidulin. They demonstrated good hemocompatibility (3.60%) and thrombolytic activity (69.62%). Selective cytotoxicity towards MCF-7 cells (IC Conclusion: HIS-CMC NPs exhibit improved stability, sustained release and enhanced biological activity, indicating their potential as an effective nanocarrier for anticancer applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.